Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for 908 Devices Inc. (NASDAQ: MASS) provides access to the company’s official U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain the contents of each document. As an emerging growth company listed on The NASDAQ Global Market, 908 Devices files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, among other documents.
In its filings, 908 Devices reports financial performance and segment details related to its portfolio of purpose-built handheld devices for chemical analysis. Investors can review product revenue, service and contract revenue, OEM and funded partnership revenue, recurring revenue associated with its installed base, and information on cost of revenue, operating expenses and net income or loss from continuing operations. The company also discloses non-GAAP metrics such as adjusted gross profit, adjusted gross margin and adjusted EBITDA, along with reconciliations to the nearest GAAP measures.
Form 8-K filings highlight material events such as quarterly earnings releases and changes in the Board of Directors. For example, recent 8-Ks have furnished press releases announcing financial results for specific quarters and documented the resignation of a director and appointment of a new director with extensive experience in nuclear, chemical and biological defense programs. These filings also confirm the company’s listing details and emerging growth company status.
Through this page, users can also monitor equity and governance disclosures, including information on non-employee director compensation, stock option and incentive plans, and any future insider transaction reports on Form 4 when available. Stock Titan’s AI tools summarize lengthy filings, highlight key figures and definitions, and surface important changes in revenue composition, operating expenses, contingent consideration, restructuring charges and other items that affect 908 Devices’ financial profile.
By combining real-time EDGAR updates with plain-language AI explanations, this filings hub helps readers quickly understand how 908 Devices is performing, how it uses non-GAAP measures, and how governance and strategic decisions are reflected in its regulatory record.
908 Devices Inc. senior vice president Kevin J. McCallion exercised employee stock options and immediately sold the resulting shares in planned trades. He exercised options for 24,000 shares of common stock at $1.05 per share, then sold 24,000 shares in open-market transactions at weighted-average prices around $7.04 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the timing was scheduled in advance. After these transactions, McCallion directly holds 44,925 shares of 908 Devices common stock.
908 Devices Inc. director Christopher D. Brown reported open-market sales of 40,000 shares of Common Stock. The transactions occurred over three days at prices around $7 per share, under a Rule 10b5-1 trading plan adopted on November 24, 2025.
Brown sold 15,030 shares at a weighted average price of $7.05 on April 8, 7,392 shares at $7.04 on April 9, and 17,578 shares at $7.07 on April 10. After these sales, he continues to hold 945,559 shares directly, indicating he retains a substantial equity position in the company.
Kevin McCallion reported a proposed sale of 27,000 shares of Common Stock via exercise of stock options on 04/08/2026. The filing lists the method as a cash exercise with sales planned through the issuer on NASDAQ. The record also lists prior 10b5-1 sales earlier in 2026 (including 9,438 and 9,000 share transactions).
908 Devices Inc. registers up to $100,000,000 of securities on a shelf for issuance from time to time. The shelf permits offerings of common stock, preferred stock, debt securities, warrants and/or units in one or more series, with specific terms set in prospectus supplements. The company’s common stock trades on the Nasdaq Global Market under the symbol MASS; the closing price reported on March 5, 2026 was $6.75 per share. The prospectus emphasizes investor risk factors and incorporates the company’s Annual Report on Form 10-K for the year ended December 31, 2025 by reference.
908 Devices Inc. files its annual report describing a business focused on handheld chemical analysis devices for critical health, safety and defense applications. The company builds portable mass spectrometry and optical spectroscopy instruments that let front-line users identify unknown drugs, explosives, toxic chemicals and gases at the point of need.
Since launching its first device in 2014, it has sold more than 3,700 handheld units to over 700 customers, including numerous government agencies, and more than 3,100 MX908 devices with over 14,000 trained operators. The report outlines its technology platform, product portfolio, manufacturing footprint, intellectual property, regulatory environment, cybersecurity posture and extensive risk factors tied to macroeconomic conditions, competition, supply chain and data security.
908 Devices Inc. executive John Kenneweg, SVP of Sales & Product Marketing, filed an initial Form 3 detailing his equity holdings in the company. The filing shows multiple stock option awards and restricted stock units, along with 57,784 shares of Common Stock held directly as of February 26, 2026.
Footnotes describe how various option grants and RSUs vest over time, with portions having already vested and remaining amounts vesting in monthly or annual installments through 2027, subject to his continued service. All entries are reported as holdings, with no explicit purchases or sales indicated in this filing.
908 Devices Inc. filed an initial Form 3 for Chief Legal and Administrative Officer Mark S. Levine, reporting existing equity awards. He holds stock options covering 130,468 shares and 98,242 restricted stock units. The options begin vesting on January 1, 2027, with one-third vesting then and the remaining two-thirds vesting in substantially equal monthly installments over the following 24 months, subject to continued service. The RSUs vest in three substantially equal annual installments on the anniversary dates following January 1, 2026, also contingent on continued service, and each RSU converts into one share of common stock when vested.
908 Devices Inc. senior vice president of Products and Production, Kevin J. McCallion, reported small insider transactions in company stock. On March 2, 2026, he exercised a stock option for 7 shares at $1.05 per share and received fully vested, immediately exercisable shares.
He then sold 7 shares of common stock at $7.00 per share in an open-market transaction made under a Rule 10b5-1 trading plan adopted on December 9, 2025. After these transactions, he directly held 26,686 option shares and 44,925 common shares.